Oct 8 (Reuters) - Pharming Group NV PHAR.AS :
* Announces that the U.S. Food and Drug Administration (FDA)
has granted 12 years of exclusivity to RUCONEST (C1 esterase
inhibitor recombinant ) 50 IU/kg
Source text for Eikon: ID:nPre7mxQ5a
Further company coverage: PHAR.AS
(Gdynia Newsroom)